The latest policy on pirfenidone medical insurance reimbursement in 2025

Pirfenidone is one of the important drugs currently used to treat idiopathic pulmonary fibrosis (IPF) and has been approved by the National Medical Products Administration and put on the market. According to the latest medical insurance policy, the original drug pirfenidone has been included in the Category B list of China’s medical insurance, and patients can reimburse part of the cost through medical insurance if they meet the indications.

According to the latest medical insurance policy, the reimbursement scope of pirfenidone mainly focuses on the indication of idiopathic pulmonary fibrosis (IPF). For patients with IPF who meet certain medical criteria, pirfenidone can be partially reimbursed by Medicare. This policy provides greater financial support to patients, especially considering that the treatment of IPF usually requires long-term medication, and the drug cost of pirfenidone may cause a greater financial burden to some patients.

However, the scope of medical insurance reimbursement also has certain limitations. Currently, medical insurance reimbursement for pirfenidone is limited to patients with idiopathic pulmonary fibrosis, and patients with other types of pulmonary fibrosis have not yet been included in the scope of reimbursement. In addition, patients need to follow the doctor’s diagnosis and treatment recommendations and ensure that they meet specific disease criteria to enjoy medical insurance reimbursement. Therefore, before treatment, patients should communicate with their doctors to confirm whether they meet the conditions for medical insurance reimbursement.

In order to allow more patients to benefit from medical insurance policies, some local governments are also implementing some local subsidies or preferential policies. Patients can learn specific reimbursement details by contacting their hospital or medical insurance department. Overall, the medical insurance reimbursement policy for pirfenidone provides effective financial support for patients who meet the indications, reducing the pressure on treatment costs for some patients.

The implementation of these medical insurance policies has greatly improved the accessibility of this drug to patients and brought more optimized treatment options to IPF patients.

Reference materials:https://www.esbriet.com/